// App-Quantinova.ai

Filters

Biomarkers











Conference Name











Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























387 Abstracts

INTRAVASCULAR IMAGING-GUIDED PERCUTANEOUS TRANSLUMINAL PULMONARY ANGIOPLASTY FOR PERIPHERAL PULMONARY STENOSIS AND PULMONARY TAKAYAS-s ARTERITIS

Ryoji Yanagisawaa - American College of Cardiology (ACC) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Chronic thromboembolic pulmonary hypertension

N/A

THE INTERMOUNTAIN MAJOR ADVERSE CARDIOVASCULAR EVENTS RISK SCORES EFFECTIVELY AND EFFICIENTLY PREDICT 1- TO 3- YEAR POST-STENT MACE IN NON-MYOCARDIAL INFARCTION PATIENTS

Benjamin Davies Hornea - American College of Cardiology (ACC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

LOW URINARY CGMP/BNP RATIO IS ASSOCIATED WITH WORSE OUTCOMES IN HEART FAILURE BUT IS INCREASED BY TREATMENT WITH SACUBITRIL/VALSARTAN: AN ANALYSIS OF PARADIGM-HF

Pardeep Jhund - American College of Cardiology (ACC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

Sacubitril/valsartan

RATIONALE AND METHODS OF THE PROSPECTIVE STUDY OF BIOMARKERS, SYMPTOM IMPROVEMENT AND VENTRICULAR REMODELING DURING ENTRESTO THERAPY FOR HEART FAILURE (PROVE-HF) STUDY

James L. Januzzia - American College of Cardiology (ACC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

Sacubitril/valsartan

SCREENING OF PATIENTS WITH SIMPLE CLINICAL PARAMETERS EARLY IN HOSPITALIZATION IS HIGHLY SENSITIVE FOR DETECTION OF HEART FAILURE HOSPITALIZATION

Robin Fortman - American College of Cardiology (ACC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

Carvedilol

PERFORMANCE OF THE MAGGIC HEART FAILURE RISK SCORE IN JAPANESE ACUTE HEART FAILURE PATIENTS: A REPORT FROM THE WEST TOKYO HEART FAILURE REGISTRY

Mitsuaki Sawano - American College of Cardiology (ACC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

B-TYPE NATRIURETIC PEPTIDE LEVELS IS A USEFUL PROGNOSTIC MARKER IN THE PATIENTS WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS

Mina Nakayama - American College of Cardiology (ACC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

HIGHER B-TYPE NATRIURETIC PEPTIDE LEVELS PREDICT OCCURRENCE OF ACUTE KIDNEY INJURY AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT

Stephan Haussig - American College of Cardiology (ACC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

N/A

N/A

PROGNOSTIC VALUE OF BASELINE N-TERMINAL PROHORMONE TYPE NATRIURETIC PEPTIDE MEASUREMENT IN CHRONIC LUNG DISEASE PATIENTS WITH SEVERE AORTIC STENOSIS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT

Pavida Pachariyanon - American College of Cardiology (ACC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

FIBROBLAST GROWTH FACTOR 23 AS NOVEL BIOMARKER FOR EARLY RISK STRATIFICATION AFTER ST-ELEVATION MYOCARDIAL INFARCTION

Martin Reindla - American College of Cardiology (ACC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

LONGITUDINAL CHANGE IN SOLUBLE ST2 VERSUS B-TYPE NATRIURETIC PEPTIDE IN PREDICTING MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ASYMPTOMATIC PATIENTS IN THE COMMUNITY

Isaac Teaa - American College of Cardiology (ACC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

MULTIDISCIPLINARY HEART FAILURE TRANSITIONAL CARE TEAM TO IMPACT READMISSIONS

Robin Fortman - American College of Cardiology (ACC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

HAND-FOOT-AND-MOUTH (AND HEART) DISEASE: COXSACKIEVIRUS A6 AS A RECENTLY RECOGNIZED CAUSE OF ACUTE MYOCARDITIS

Carly Fabrizio - American College of Cardiology (ACC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

N/A

CORONARY ARTERY ANEURYSM IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS

Kainat Khalid - American College of Cardiology (ACC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Clopidogrel bisulfate

CONSTRICTIVE PERICARDITIS DUE TO KAWASAKI DISEASE

Harshith Reddy Avula - American College of Cardiology (ACC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

SUBMASSIVE PULMONARY EMBOLISM WITH CONCOMITANT PARADOXICAL EMBOLISM THROUGH PATENT FORAMEN OVALE

Eliany Mejia Lopez - American College of Cardiology (ACC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

Methadone hydrochloride

MULTIPLE BIOMARKERS FOR PREDICTING MAJOR ADVERSE CARDIAC EVENTS IN AT-RISK PATIENTS UNDERGOING DIAGNOSTIC CORONARY ANGIOGRAPHY: RESULTS FROM THE CATHETER SAMPLED BLOOD ARCHIVE IN CARDIOVASCULAR DISEASES (CASABLANCA) STUDY

Cian McCarthy - American College of Cardiology (ACC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

B-TYPE NATRIURETIC PEPTIDE MAY PROMOTE ARRHYTHMIA IN HEART FAILURE THROUGH INHIBITING TRANSIENT OUTWARD POTASSIUM CURRENT

Junping Sun - American College of Cardiology (ACC) , 2013

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

N/A

TREATMENT WITH SPIRONOLACTONE SIGNIFICANTLY REDUCES 30-DAY HEART FAILURE MORTALITY AND REHOSPITALIZATION

Yang Xue - American College of Cardiology (ACC) , 2013

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

Spironolactone

KIDNEY DISEASE IMPROVING GLOBAL OUTCOMES (KDIGO) CLASSIFICATION FOR RISK STRATIFICATION IN HOSPITALIZED HEART FAILURE PATIENTS

Kazuhiro Yajima - American College of Cardiology (ACC) , 2013

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute decompensated heart failure

N/A

Copyright © 2026. QuantiNova All rights reserved